"Company","Parent Company","Penalty Amount","Subtraction From Penalty","Penalty Amount Adjusted For Eliminating Multiple Counting","Penalty Year","Penalty Date","Offense Group","Primary Offense","Secondary Offense","Description","Level of Government","Action Type","Agency","Civil/Criminal","Prosecution Agreement","Court","Case ID","Private Litigation Case Title","Lawsuit Resolution","Facility State","City","Address","Zip","NAICS Code","NAICS Translation","HQ Country of Parent","HQ State of Parent","Ownership Structure","Parent Company Stock Ticker","Major Industry of Parent","Specific Industry of Parent","Info Source","Notes"
"Aegerion Pharmaceuticals Inc.","Amryt Pharma","$35,000,000","$0","$35,000,000","2017","20170922","safety-related offenses","drug or medical equipment safety violation","False Claims Act and related","Aegerion Pharmaceuticals Inc., a Cambridge, Massachusetts-based subsidiary of Novelion Therapeutics Inc., agreed to plead guilty to charges that that its prescription drug Juxtapid was misbranded because, among other things, Aegerion failed to comply with a Risk Evaluation and Mitigation Strategy (REMS). The resolution also included a deferred prosecution agreement relating to criminal liability under the Health Insurance Portability and Accountability Act of 1996 (HIPAA). In addition, Aegerion agreed to settle allegations that it caused false claims to be submitted to federal health care programs for Juxtapid. Aegerion agreed to pay more than $35 million to resolve criminal and civil liability arising from these matters.","federal","agency action","Justice Department Civil Division","civil and criminal","deferred prosecution agreement","","","","","","","","","","","United Kingdom","","publicly traded","","pharmaceuticals","pharmaceuticals","https://www.justice.gov/opa/pr/drug-maker-aegerion-agrees-plead-guilty-will-pay-more-35-million-resolve-criminal-charges-and",""
"Aegerion Pharmaceuticals","Amryt Pharma","$4,100,000","$0","$4,100,000","2017","20170922","financial offenses","investor protection violation","","","federal","agency action","Securities and Exchange Commission","civil","","","","","","Massachusetts","","","","","","United Kingdom","","publicly traded","","pharmaceuticals","pharmaceuticals","https://www.sec.gov/litigation/litreleases/2017/lr23942.htm",""
"Aegerion Pharmaceuticals Inc.","Amryt Pharma","$2,700,000","$2,700,000","$0","2017","20170922","government-contracting-related offenses","False Claims Act and related","","Aegerion agreed to pay $2.7 million to settle multistate litigation alleging it improperly marketed its drug Juxtapid and thus cause false claims to be submitted to Medicaid programs. This was part of a larger $35 million settlement involving the federal government; see the Violation Tracker entry at https://violationtracker.goodjobsfirst.org/violation-tracker/-aegerion-pharmaceuticals-inc","state","agency action","Multistate Attorneys General Case","civil","","","","","","","","","","","","United Kingdom","","publicly traded","","pharmaceuticals","pharmaceuticals","https://www.justice.gov/opa/pr/drug-maker-aegerion-agrees-plead-guilty-will-pay-more-35-million-resolve-criminal-charges-and",""
